Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01739933 · ClinicalTrials.gov registry record · Phase 3
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
A Phase 3 study of Sepsis and Delirium, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 438
- Enrollment target
- 11
- Study locations
NCT01739933 is a Phase 3 study of Sepsis and Delirium that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 438 participants, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT01739933, a Phase 3 study of Sepsis and Delirium, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 438 participants
- Enrollment target
- 11
- Study locations
Study Summary
Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in survivors. Universally prescribed sedative medications-the GABA-ergic benzodiazepines-worsen this brain organ dysfunction. The available alternative sedation regimens, the shorter acting GABA-ergic propofol, and the alpha2 agonist, dexmedetomidine, have both been shown to be superior to benzodiazepines, and yet are different with regard to their effects on innate immunity, bacterial clearance, apoptosis, cognition and delirium. The MENDS2 study will compare propofol and dexmedetomidine, and determine the best sedative medication to reduce delirium and improve survival and long-term brain function in our most vulnerable patients- the ventilated septic patient.
Conditions Studied
Interventions
- DRUG Dexmedetomidine
- DRUG Propofol
Study Locations (11)
Texas
- Texas Health Harris Fort Worth - Fort Worth
- Baylor College of Medicine - Houston
- Houston Methodist Hospital - Houston
- University of Texas Health Science Center at San Antonio - San Antonio
Massachusetts
- Tufts Medical Center - Boston
- Baystate Medical Center - Springfield
California
- University of California, San Francisco - San Francisco
Louisiana
- Baton Rouge General Medical Center and Our Lady of The Lakes Regional Medical Center - Baton Rouge
North Carolina
- Mission Hospital - Asheville
Tennessee
- Vanderbilt University Medical Center - Nashville
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2013-05-15 |
| Est. Completion | 2019-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01739933
The ClinicalTrials.gov registry entry for NCT01739933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Dexmedetomidine is the first listed.
NCT01739933 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Texas, Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT01739933 about?
NCT01739933 is a clinical study titled "The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure". Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in survivors. Universally prescribed sedative medications-the GABA-ergic b...
What is the current status of trial NCT01739933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 438 participants. The study started on 2013-05-15. Estimated completion is 2019-07.
What conditions does trial NCT01739933 study?
This clinical trial studies the following conditions: Sepsis, Delirium, Impaired Cognition.
What interventions are being tested in trial NCT01739933?
The interventions under investigation include: Dexmedetomidine (DRUG), Propofol (DRUG).
Who is sponsoring clinical trial NCT01739933?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01739933 being conducted?
This trial has 11 study locations across California, Louisiana, Massachusetts, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
RECRUITING · Phase 3
-
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RECRUITING · Phase 3
-
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
COMPLETED · Phase 3
-
Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants
COMPLETED · Phase 3
-
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
COMPLETED · Phase 3
-
The APS Phenotyping Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.